A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Frontiers in Medicine

Medicine

Khalid Ahmed¹  Wafer A. Dabdoob¹  Mohamed A. Yassin²  Rasha Kaddoura² 

[1] Hamad Medical Corporation, Doha, Qatar;null;

关键词: chronic myeloid leukemia;    tyrosine kinase;    heart failure;    pulmonary arterial hypertension;    QT prolongation;    dasatinib;    ponatinib;    pleural effusion;   

DOI  :  10.3389/fmed.2023.1163137

 received in 2023-02-10, accepted in 2023-04-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.

【 授权许可】

Unknown   
Copyright © 2023 Kaddoura, Dabdoob, Ahmed and Yassin.